Loading…
Based on limited metadata, the FDA issued a warning letter to Euphoria Healthcare Pvt Ltd. on September 6, 2019, regarding drug manufacturing or distribution operations. Without access to the full warning letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the complete details of the compliance issues cited, the full warning letter would need to be reviewed.